- Language: English
- 1113 Pages
- Published: July 2012
- Region: Global
Global Epilepsy Market 2010-2014
- Published: February 2012
- Region: Global
- 29 pages
- Infiniti Research Limited
TechNavio’s analysts forecast the Global Epilepsy market to reach US$8.1 billion by 2014. One of the key factors contributing to this market growth is increasing usage of second-generation drugs. The Global Epilepsy market has also been witnessing a reduction of prices of anti-epileptic drugs. However, intense competition among manufacturers could pose a challenge to the growth of this market.
TechNavio’s report, the Global Epilepsy Market 2010–2014, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the first-line therapies and the second-line therapies and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and UCB SA.
Key questions answered in this report:
What will the market size be in 2014 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
Large Aging Population Key Users of AEDS
TechNavio today published its report Global Epilepsy Market 2010–2014. The report discusses the key trends impacting the growth of this market.
TechNavio’s report highlights the Global Epilepsy market is driven by the rise in the aging population. According to the WHO, up to 50 million people worldwide, amounting to at least 50 per 100,000 people of the general population will have epilepsy at any one time. When compared to the younger population, the aged population has a higher incidence of epileptic seizures, which results in repeated acute seizures. This creates the demand for automated external defibrillator (AEDs).
Commenting on the report, an analyst from TechNavio’s Healthcare team said, “Issues such as patent expirations, consumer affordability, etc., have pushed vendors to develop more economical AEDs. The AED market is currently under pressure due to competition from generic drugs, which are typically 40–50 percent cheaper. This can drive down the prices and decrease the sales of branded drugs. As a result AED vendors have stepped up and are focusing on economical options for patients.
Key findings from the report:
- Increasing Usage of Second-generation Drugs
- Behavioral Change Among Anti-epileptic Drug Users
- Prices of Anti-epileptic Drugs to be Reduced
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
SHOW LESS READ MORE >
01. Executive Summary
03. Market Coverage
04. Market Landscape
05. Vendor Landscape
06. Buying Criteria
07. Market Growth Drivers
08. Drivers and their Impact
09. Market Challenges
10. Market Trends
11. Key Vendor Analysis
11.1 Pfizer Inc.
11.2 UCB SA
11.3 GlaxoSmithKline plc.
11.4 Novartis AG
12. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Epilepsy Market 2010–2014 (US$ billions)
Exhibit 2: Global Epilepsy Market by Geographical Segmentation 2010
Exhibit 3: Global Epilepsy Market by Vendor Segmentation 2010
- Pfizer Inc.
- UCB SA
- GlaxoSmithKline plc.
- Novartis AG